Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Kidney cancer

Single nucleotide polymorphisms in mRCC—is their time up?

Nature Reviews Urology volume 12, pages 424–426 (2015)Cite this article

Subjects

A large validation study on the effect of single nucleotide polymorphisms on outcome and adverse events in sunitinib-treated patients with metastatic renal cell carcinoma (mRCC) only confirmed that ABCB1 and CYP3A5 variants are associated with progression-free survival and dose reductions, respectively. Does this mean 'game over' for polymorphism research in mRCC?

Refers to Diekstra, M. H. M. et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.04.018

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Beuselinck, B. et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 108, 887–900 (2013).

    Article  CAS  Google Scholar 

  2. van der Veldt, A. A. et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17, 620–629 (2011).

    Article  CAS  Google Scholar 

  3. Garcia-Donas, J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 12, 1143–1150 (2011).

    Article  CAS  Google Scholar 

  4. Motzer, R. J. et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 74, 739–750 (2014).

    Article  CAS  Google Scholar 

  5. Diekstra, M. H. M. et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2015.04.018.

  6. Xu, C. F. et al. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br. J. Cancer 112 (Suppl.), 1190–1198 (2015).

    Article  CAS  Google Scholar 

  7. Beuselinck, B. et al. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncol. 53, 1–10 (2014).

    Article  Google Scholar 

  8. Mizuno, T. et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther. Drug Monit. 36, 310–316 (2014).

    Article  CAS  Google Scholar 

  9. Diekstra, M. H. et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin. Pharmacol. Ther. 96, 81–89 (2014).

    Article  CAS  Google Scholar 

  10. Beuselinck, B. et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib—a multicentric retrospective analysis. Acta Oncol. 53, 103–112 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medical Oncology and Laboratory for Experimental Oncology, University Hospitals Leuven, KU Leuven, Herestraat 49, Leuven, B-3000, Belgium

    Benoit Beuselinck

  2. Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, Institut Universitaire d'Hématologie (IUH), Rue Juliette Dodu 27, Paris, F-75010, France

    Jessica Zucman-Rossi

Authors
  1. Benoit Beuselinck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica Zucman-Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benoit Beuselinck.

Ethics declarations

Competing interests

B.B. is an investigator of the EudraCT: 2011-006085-40/MetaSun trial supported by Pfizer and has received honoraria for educational activities from Amgen and GlaxoSmithKline. J.Z.-R. has received honoraria from Astellas, Bayer, Lilly and Pfizer.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beuselinck, B., Zucman-Rossi, J. Single nucleotide polymorphisms in mRCC—is their time up?. Nat Rev Urol 12, 424–426 (2015). https://doi.org/10.1038/nrurol.2015.149

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2015.149

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing